文献速递呼吸道感染

印度支气管扩张症患者的临床结局:EMBARC-印度登记研究数据

Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry.
PubMed 文献 · Eur Respir J · 2023-01-06

该研究基于EMBARC-印度登记研究,纳入1018例CT确诊的成人支气管扩张症患者并随访至少12个月,分析基线特征与死亡、重度急性加重、总体急性加重频率及FEV1下降的关联。结果显示基线频繁急性加重、合并慢阻肺、呼吸困难、当前吸烟、年龄增长及心血管合并症与不良结局相关,革兰阴性菌感染(主要为肺炎克雷伯菌)与死亡率升高独立相关,铜绿假单胞菌感染与重度急性加重及总体急性加重率相关。

要点

  • 基线每年急性加重≥3次与死亡、重度急性加重、未来急性加重及肺功能下降风险升高相关。
  • 合并慢阻肺、呼吸困难、当前吸烟与所有研究终点的更差结局相关。
  • 革兰阴性菌感染(主要为肺炎克雷伯菌)与死亡率升高独立相关。

核心结论

  • 研究识别了印度支气管扩张症患者发病和死亡的风险因素,可能支持针对亚洲人群优化的治疗策略。

研究设计与样本

  • EMBARC-印度登记研究为前瞻性观察性研究,纳入印度31个中心CT确诊的成人支气管扩张症患者,1018例有至少12个月随访数据者进入随访分析。

主要发现

  • 基线频繁急性加重(每年≥3次)与死亡率升高相关(HR 3.23,95%CI 1.39-7.50)。
  • 基线频繁急性加重与重度急性加重相关(HR 2.71,95%CI 1.92-3.83)。
  • 基线频繁急性加重与未来急性加重相关(IRR 3.08,95%CI 2.36-4.01)并与肺功能下降相关。
  • 合并慢阻肺、呼吸困难及当前吸烟与所有研究终点的更差结局相关。
  • 革兰阴性病原体感染(主要为肺炎克雷伯菌)与死亡率升高独立相关(HR 3.13,95%CI 1.62-6.06);铜绿假单胞菌感染与重度急性加重相关(HR 1.41,95%CI 1.01-1.97)并与总体急性加重率相关(IRR 1.47,95%CI 1.13-1.91)。

关键数值与推荐

  • 死亡和重度急性加重的额外预测因素包括年龄增长和心血管合并症。

临床怎么用

  • 对支气管扩张症患者应关注基线急性加重频率、合并慢阻肺、呼吸困难、吸烟史、年龄及心血管合并症以进行风险分层。
  • 对检出革兰阴性菌(尤其肺炎克雷伯菌)或铜绿假单胞菌感染的患者,可考虑更密切监测和针对性治疗。

局限性

  • 研究基于印度人群,结果外推至其他亚洲或西方人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identifying risk factors for poor outcomes can help with risk stratification and targeting of treatment. Risk factors for mortality and exacerbations have been identified in bronchiectasis but have been almost exclusively studied in European and North American populations. This study investigated the risk factors for poor outcome in a large population of bronchiectasis patients enrolled in India. METHODS: The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India (EMBARC-India) registry is a prospective observational study of adults with computed tomography-confirmed bronchiectasis enrolled at 31 sites across India. Baseline characteristics of patients were used to investigate associations with key clinical outcomes: mortality, severe exacerbations requiring hospital admission, overall exacerbation frequency and decline in forced expiratory volume in 1 s. RESULTS: 1018 patients with at least 12-month follow-up data were enrolled in the follow-up study. Frequent exacerbations (≥3 per year) at baseline were associated with an increased risk of mortality (hazard ratio (HR) 3.23, 95% CI 1.39-7.50), severe exacerbations (HR 2.71, 95% CI 1.92-3.83), future exacerbations (incidence rate ratio (IRR) 3.08, 95% CI 2.36-4.01) and lung function decline. Coexisting COPD, dyspnoea and current cigarette smoking were similarly associated with a worse outcome across all end-points studied. Additional predictors of mortality and severe exacerbations were increasing age and cardiovascular comorbidity. Infection with Gram-negative pathogens (predominantly Klebsiella pneumoniae) was independently associated with increased mortality (HR 3.13, 95% CI 1.62-6.06), while Pseudomonas aeruginosa infection was associated with severe exacerbations (HR 1.41, 95% CI 1.01-1.97) and overall exacerbation rate (IRR 1.47, 95% CI 1.13-1.91). CONCLUSIONS: This study identifies risk factors for morbidity and mortality among bronchiectasis patients in India. Identification of these risk factors may support treatment approaches optimised to an Asian setting.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Dhar, Singh, Talwar, et al. Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry. Eur Respir J. 2023. PMID: 36229049. doi:10.1183/13993003.00611-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。